INTRODUCTION
The first TNM staging system for renal tumours was released in 1978 1 . It is the standard staging classification for renal cell carcinoma (RCC) with the pathological stage being the mainstay to assess survival prognosis 2, 3 . Besides TNM, other factors that may influence prognosis in RCC have been identified. Clinical factors include symptoms at presentation by opposition to incidental diagnosis and ECOG performance status at diagnosis, laboratory parameters as thrombocytes and haemoglobin level and pathological factors as Fuhrman grade and the presence of tumour necrosis 4 . Moreover, the discovery of the von Hippel-Lindau gene led to the description of several biomarkers involved in the pathogenesis of RCC and of possible prognostic significance 5, 6 . In attempts to assess prognosis more accurately, prognostic systems and nomograms combining some of these factors have been developed for different settings in RCC 4, 7, 8 . In preoperative prognostic models clinical and radiological factors are combined. Pathological and clinical factors are incorporated in postoperative models. Prognostic systems for metastatic RCC incorporate clinical and laboratory variables. While internal validation is available for most of these models, external validation in different populations than the developmental one is essential prior to implementation and widespread use of a model or nomogram 9 . Currently many prognostic integrated systems are available for RCC, however sound data about their use in clinical practice is lacking.
Primary objective of this study was to evaluate the use of prognostic factors and models in RCC among urologists. Secondary objective was to gather the negative motivations that preclude the use of prognosticators/prognostic models and to identify demographic factors associated with the use of models or biomarkers.
MATERIALS AND METHODS

Recruitment
A survey was conducted among the principal investigators of active centres participating in the Clinical Research Office of the Endourological Society (CROES) Renal Mass Study. A personalized questionnaire was distributed by e-mail between February 2011 and March 2012. Forms could be returned by email or fax. Three e-mail waves were sent and the inclusion closed in May 2012. No approval of the ethical committee was needed for this study.
Questionnaire
To confection the questionnaire a literature review was performed on prognostic models and factors. MeSH terms "prognosis, risk factor, survival, prognostic factor, model, nomogram, integrated staging system, validation, and calibration plot" were crossed each with "renal cell carcinoma". Related key papers' references were meticulously studied. Besides the TNM, other prognostic systems were selected based on introduction of original variables, description in high impact factor journals, presence of validation studies or high predictive accuracy. The prognostic systems selected for the questionnaire are displayed in Table 1 10-23 .
The questionnaire contained 20 questions (Addendum 2) divided in 3 sections. The first section (6 questions) explored demographic and global data on prognosis estimation. The second section (7 questions) assessed the use of TNM and other clinical, laboratory, pathological parameters and markers. Section 3 (7 questions) contained questions on the use of other prognostic models and opinions on their usefulness.
Data for age and years as certified urologists (questions 1-2) was numerical; questions exploring absolute frequencies (1-5, 7-9 and 14) required a unique response. The rest of the questions were multiple choices and multiple responses could be chosen but for question 6 that assessed the most important reason to "not to estimate prognosis". Questions 6 and 20 ("usefulness of prognostic models") had space for free text. 
Statistical analysis
RESULTS
From 110 active centres of the CROES Renal Mass Study 86 (78.2%) questionnaires were returned and included in the analyses. All responders were certified urologists. Demographic data of the responders is displayed in Table 2 . Most important reasons to skip prognostic estimation are illustrated in Figure 1 . Table 3 shows frequencies on the use of the TNM staging and other models for prognosis estimation. Overall 39 responders (45.3%) did not utilize other prognostic models than the TNM. Motivations not to use other models were: "too little additional value" and "not being familiar with the model" indicated by 26 (30.2%) and 24 (27.9%) responders respectively. The numbers within the figure correspond to the number of responders who selected the answer and the percentages are calculated over the total responders. The percentages mentioned on the y-axis are calculated over the number of urologists who answered this question in the survey (n=40). According to the survey this question was exclusive for those that estimate prognosis.
Number of responders 86
Median From the responders 51 (59.3%) preferred to use nomograms/models in postoperative and 48 (55.8%) in metastatic setting by opposition to 31 in local disease (36%) and 27 in preoperative setting (31.4%). The usefulness of prognostic models was quoted as: "dividing patients into risk groups" by 59 responders (68.6%), "providing patient specific information" by 50 (58.1%), and "select patients for adjuvant therapy" and "tailor followup" by 39 responders each (45.3%).
Additional clinical, laboratory and pathological factors were taken into account for prognostic purposes by 77 (89.5%) of the responders. Table  4 shows the frequencies of use for the factors mentioned in our survey. Molecular markers were utilized by 14 (16.3%) of the responders. Among them VEGF(R) was the most frequently used marker by 15.1% of the responders (n=13), 9.3% used p53 (n= 8), 5.8% used CAIX and Ki-67 (n= 5 each) and 1.2% used Vimentin and p21 (n=1 each). 2 . 3 urologists used 2 models and 2 urologists used 3 or more models; 1 used models not specified in the questionnaire. 3 . 1 urologist used all 4 specified models. Table 5 depicts the detailed association between the use of markers and models and demographic factors. No association was found between the use of markers and the use of prognostic systems (p=0.17) and the use of other models than TNM and additional clinical or pathological parameters (p= 0.20).
DISCUSSION
We gathered information on current use of prognostic models and clinical / pathological factors of possible prognostic value in RCC by approaching a convenience sample, which consisted of principal investigators of the prospective CROES renal mass study (2010-2012), a contemporary registry on patterns of treatment of renal tumours 24 . In this way we aimed to ensure that the sample represented the target population: urologists treating RCC and familiar with prognostic models and factors related to the condition. In our sample the use of models or markers was not related to any demographic data concerning age of the responder and years or type of practice. 
Number of responders (%)
Additional
Prognostic estimation and the use of prognostic models
Our survey shows that the TNM classification is universally used in RCC. Furthermore 44% and 24.5% of the urologists estimates prognosis in all and most of the RCC cases respectively. This data confirms the excellent penetration of the TNM classification whether as clinical tool in treatment decision 2, 3 or as predictor system. The pathological TNM is not only a powerful predictor for cancer specific survival with accuracy of 85% 25 and may drive the opportunity for adjuvant survival management in the future 25, 26 , but is also helpful in designing follow-up schemes. Besides general acquaintance with the TNM classification, as oldest in use, present results support its "friendly use" and generality 27 .
However, there is a discrepancy between the rate of responders that acknowledge estimating prognosis and the figures on the use of the TNM. The prognostic value of the TNM seems to be somehow underestimated or forgotten as less than half of the responders estimate prognosis in all cases. Although this figure is upgraded to 69% when including those that estimate prognosis in most of the cases, still one third of the responders might consider the TNM as a mere classification and associate prognosis estimation with the use of other prognostic systems than the TNM.
Preoperative prognostic systems using only clinical and radiological factors were marginally utilised by our responders. Usefulness of preoperative models is a matter of debate. Preoperative determination of recurrence risk or survival is not likely to influence the treatment decision that mainly depends on clinical TNM stage and patient characteristics 2, 3 . Moreover prognosis estimations with postoperative data is equally or more accurate than preoperative estimation [10] [11] [12] [13] . Nevertheless in the current interventional scenario a certain number of patients with small renal masses treated by ablation or surveyed may still benefit on the use of these preoperative models as not definitive pathology, based on surgical specimen, will be available to properly staging tumours 11 .
Our survey indicates a moderate penetration of postoperative models, although there was no clear preference for any model. Survival outcomes, patient population and performance, mostly expressed as concordance -indexes, (c-indexes) among these models and their external validation studies differ widely in the literature [14] [15] [16] [17] . The c-index of the 2002 TNM ranges from 0.746-0.848 for the T-stage 13, 18, 25 . Until date only few models have shown a higher c-index in other settings than their developmental one 28 . Furthermore validation has either failed or is not available for some. On internal validation an accuracy of 1.0 meaning perfect prediction, is never expected. However to provide incremental value to the TNM classification, the existing models should approach an accuracy of 0.9 on external validation, which none currently do 8 .
Use of prognostic models in metastatic RCC
The use of prognostic models in metastatic setting was moderate (38.4%). The professional profile of the sample, exclusively urologists, may be the explanation. Although the number of cases of metastatic RCC seen by individual/year was not recorded it might be relatively low and likely a survey focusing on oncologists would have shown different results. The figure hereby presented may be discussed under two different perspectives. For those countries where Uro-oncologists are entitled to medically treat metastatic RCC, this figure is a pessimistic one as risk prognostic assessment in metastatic RCC is of outmost importance to determine treatment. Conversely for those countries where metastatic RCC is directly under supervision of Onco-urological specialists the figure shows a nonnegligible interest of urologists in metastatic RCC prognostic estimation. The authors consider that country based surveys on this specific point would provide a better answer. As expected the Motzer model was by far the most frequently used in metastatic setting 20 . The accuracy of this model ranges from 52 to 73% including some reports on VEGF targeted therapy 8 . The Choueiri model 22 for which no internal or external c-indexes are provided, was much lesser used.
Use of additional factors
Almost 90% of the urologists indicated to take clinical, laboratory and pathological parameters into account when estimating prognosis. Approximately 80% of the urologists used several of these factors and more than half also used 3 or more different factors of one category. Although the use of additional factors did not correlate with the use of other prognostic systems than the TNM, this data indicates a strong awareness of the urological community on the possible prognostic impact of symptoms, histological subtype and nuclear grade.
Although some studies reported Fuhrman grade, symptomatic presentation, ECOG performance status or age as independent predictors for survival, other factors as subtype, haemoglobin and thrombocytes level still show conflicting results 4 . In spite of their frequent use no uniform interpretation for risk of death or disease free survival (DFS) exists for these factors. A small percentage of urologists indicated to use markers for prognostic purposes. Their use as integrated model was negligible. It's worth mentioning that recently a model integrating biomarkers has shown a high additional predictive value (c-index 0.904) for DFS in localized RCC 18 . Besides the fact that most of the biomarkers models are of recent publication, the absence of consistent results on the value of individual markers as well as cost issues limit their current use as prognostic tools 29 .
Although the subject is the object of sharp research a longer period of time is necessary to assess the true impact of such models. Their generality will ultimately depend on their additional value when combined with other prognostic systems at use and their availability.
Reasons to skip prognostic estimation
The main reason to preclude prognosis estimation reported by half of the responders of this question was the lack of accuracy of the different prognostic systems/factors. Other reasons in decreasing order were lack of additional benefit, absence of clinical relevance and being time consuming. These opinions reflect the well-known concerns on the external performance of prognostic systems 27, 29 and open the door for a critical assessment on the developmental methodology of prognostic systems in cancer, on their usefulness in the current treatment practice in RCC and on their functionality.
In response to the more specific question on the reason for not using other models than TNM, again most important reason was lack of additional value and one third of the urologists indicated that not being familiar with models was the reason not to use them. Seeing that the questionnaire was spread among research minded urologists, the actual number of urologists who are not familiar with prognostic systems will likely be higher.
Limitations
The limitations of our study include: models selection, population sample and geographical distribution of the responders. Not all the models described in the literature were included in our survey. Inclusion of all reported models will have lengthened the questionnaire and most likely decreased the response rate, which was higher than expected in this kind of surveys. The convenience sample was dictated by the focused practice. In fact it is impossible to assess the potential population, as no data is available on the total number of Uro-oncologists and most specifically those dedicated to RCC. Although this figure is expected to be very high, a power calculation shows that the high response rate of our survey provided the sample with a 95% of confidence (± 10% of variability) and thus could be considered representative. The use of a convenience sample precludes extrapolation on the use of models and markers among general urologists not involved in oncology. The figures hereby presented might be even lower should general urologist have been surveyed. This is a further point of concern when considering the usefulness of more complex predictive models than the TNM. With respect to the geographical distribution, as 70% of the responders belonged to European countries, we cannot ensure that the results can be extrapolated to other continents. There were no apparent differences in response results between European and American urologists but the American sample was scarce.
CONCLUSIONS
The TNM staging system is universally used although only 40% of the urologists acknowledge assessing prognostic in RCC. Preoperative prognostic models are scarcely used and postoperative models are only moderately used. There is no clear preference for any of the postoperative models. The main reasons that hinder the use of other prognostic models than the TNM are lack of accuracy, absence of additional benefit and lack of familiarity with. In metastatic setting the Motzer model is the most frequently used. Clinical, laboratory and pathological factors are being used by almost all urologists. Our data indicates that the penetration of the recently described staging models and integrated systems is at the most moderate, suggesting a limited use outside of the original developmental settings.
